Try our mobile app

General information

Country: UNITED STATES

Sector: Medical Devices

Abbott Laboratories discovers, develops, manufactures, and sells a broad and diversified line of health care products and services. The Company"s products include pharmaceuticals, nutritional, diagnostics, and vascular products. Abbott markets its products worldwide through affiliates and distributors.
Website: abbott.com


  • Good financial results growth rate 13.8% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (-4.0%)
  • Dividend yield for the last twelve months 1.7%
  • Free cash flow yield 0.6% (LTM)
  • Share price is 47.4% higher than minimum and 5.2% lower than maximum for the last 3 years
  • The company is undervalued by EV / LTM EBITDA multiple compared to target level (26.9x vs
    )
  • Fundamental value created in LTM (estimate)
  • For the last 3 months insiders sold company shares on $0.7 mln (0.000% of cap.)

Key Financials (Download financials)

Ticker: ABT
Share price, USD:  (+0.6%)132.96
year average price 125.01  


year start price 113.10 2024-09-05

min close price 111.10 2025-01-15

max close price 140.22 2025-03-03

current price 132.18 2025-09-04
Common stocks: 1 746 881 140

Dividend Yield:  1.7%
FCF Yield LTM: 0.6%
EV / LTM EBITDA: 26.9x
EV / EBITDA annualized: 24.6x
Last revenue growth (y/y):  +7.4%
Last growth of EBITDA (y/y):  +20.3%
Historical revenue growth:  -1.5%
Historical growth of EBITDA:  -6.6%
Target EV / EBITDA (hist percentile):
Express share price potential:
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 232 265
Net Debt ($m): 6 430
EV (Enterprise Value): 238 695
EBITDA LTM ($m): 8 881
EV / LTM EBITDA: 26.9x
Price to Book: 5.8x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-09-01zacks.com

ABT Stock Gains From Navitor's Expanded Indication Approval in Europe

2025-08-29zacks.com

ABT vs. EW: Which Structural Heart Device Stock Is Worth Buying Now?

2025-08-29prnewswire.com

Abbott's Navitor™ TAVI System Receives CE Mark for Expanded Indication to Treat More People With Aortic Stenosis

2025-08-27zacks.com

What's Driving Abbott's Gross Margin Growth Amid Macro Issues

2025-08-18zacks.com

Abbott Gains in Nutrition With Adult Segment Leading Growth

2025-08-14zacks.com

Abbott Taps Growing TMVR Market With Tendyne System

2025-08-12reuters.com

Abbott India's profit climbs on healthy pharmaceutical demand

2025-08-09seekingalpha.com

Abbott Laboratories Q2 Earnings: Dividends Don't Lie

2025-08-06zacks.com

Abbott's Q2 Diabetes Care Sales Rise 19.6%: What's Backing It?

2025-07-28247wallst.com

3 Dividend Growth Stocks That Will Deliver Meaty Returns After 5 Years
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data